Skip to main content
Article thumbnail
Location of Repository

The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development

By Noah S. Philip, Linda L. Carpenter, Audrey R. Tyrka and Lawrence H. Price


An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). This receptor, which is distributed widely in regions of the brain associated with depression, is also implicated in other important processes that are relevant to depression, such as stress and inflammation. The two classes of drugs that target nAChRs can be broadly divided into mecamylamine- and cytisine-based compounds. These drugs probably exert their effects via antagonism at α4β2 nAChRs, and strong preclinical data support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants (e.g., monoamine reuptake inhibitors). Although clinical data remain limited, preliminary results in this area constitute a compelling argument for further evaluation of the nAChR as a target for future antidepressant drug development

Topics: Review Article
Publisher: The Scientific World Journal
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2009). A l b u q u e r q u e
  2. (2009). A n d r e a s e n ,G .M .O l s e n ,O .W i b o r g ,a n dJ .P .R e d r o b e , “Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests,”
  3. (2008). Acetylcholine receptors in dementia and mild cognitive impairment,”
  4. (1999). Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines,”
  5. (1998). Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats,”
  6. (2010). arpent er ,A.R.T yrka,andL.H.P ric e,“N icotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature,”
  7. (2009). Biological basis for the comorbidity between smoking and mood disorders,”
  8. (2006). Brain nicotinic acetylcholine receptors: native subtypes and their relevance,”
  9. (2008). C i n c o t t a ,M .S .Y o r e k ,T .M .M o s c h a k
  10. (2012). Chemistry and behavioral studies identify chiral cyclopropanes as selective alpha4beta2-Nicotinic Acetylcholine receptor partial agonists exhibiting an antidepressant profile,”
  11. Chemistry and pharmacology of nicotinic ligands based on 6-
  12. (2004). Cholinergic modulationofmicroglialactivationbyα7nicotinicreceptors,”
  13. (1995). Chronic desipramine alters stress-inducedbehaviorsandregionalexpressionoftheimmediate early gene,
  14. (2007). Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking,”
  15. (2012). Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of
  16. (2005). Comparison of alterations in c-fos and egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds,” Neuropsychopharmacology,v o l .3 0 ,n o .7 ,p p .
  17. (2006). Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy,”
  18. (2009). Cytisine-based nicotinic partial agonists as novel antidepressant compounds,”
  19. (2007). Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male c57bl/6j mice,”
  20. (2007). Depression during tobacco abstinence,”
  21. (1977). Depression: a new animal model sensitive to antidepressant treatments,”
  22. (2006). Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists,”
  23. (2011). Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial,”
  24. (2011). Discovery of isoxazole analogues of sazetidine-A as selective alpha4beta2-nicotinic acetylcholine receptor partial agonists for the treatment of depression,”
  25. (2011). Dissociation betweendurationofactionintheforcedswimtestinmiceand nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-i-a85380,”
  26. (1998). Effects of fluoxetine on wild and mutant neuronal α7 nicotinic receptors,”
  27. (2006). Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial,”
  28. (2008). Exacerbation of recurrent depression as a result of treatment with varenicline,”
  29. (2007). Exacerbation of schizophrenia by varenicline,”
  30. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events,”
  31. (2008). G e o r g e ,K .A .S a c c o ,J .C .V e s s i c c h i o
  32. (2009). Gronlien et al., “Stimulation of dopaminereleasebynicotinicacetylcholinereceptorligandsin rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination,”
  33. (2009). H.Rollema,V.Guanowsky,Y.S.Mineuretal.,“Vareniclinehas antidepressant-like activity in the forced swim test and augments sertraline’s effect,”
  34. (2009). hex-5-yn-1-ol (amoph-oh) for possible use in depression,”
  35. (2004). High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptylineonbehaviorandhippocampalcellproliferation,”
  36. (1999). i z a b i ,D .H .O v e r s t r e e t ,A .H .R e z v a n ie ta l . ,“ A n t i d e p r e s -sant effects of nicotine in an animal model of depression,”
  37. (2012). Identification of Novelalpha4beta2-NicotinicAcetylcholineReceptor(nAChR) agonists based on an isoxazole ether scaffold that cemonstrate antidepressant-like activity,”
  38. (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression,”
  39. (1995). Interleukin-2 (il2) induces corticotropin-releasing factor (crf) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response,”
  40. (2008). It is not “either/or”: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood,”
  41. (1998). ın, “Effects of nicotine and mecamylamine on rat dorsal raphe neurons,”
  42. (2010). J.Z.Guo,E.M.Sorenson,andV.A.Chiappinelli,“Cholinergic modulation of non-N-methyl-D-aspartic acid glutamatergic transmission in the chick ventral lateral geniculate nucleus.,”
  43. (2003). K.G.ParadisoandJ.H.Steinbach,“Nicotineishighlyeffective at producing desensitization of rat α4β2neuronal nicotinic receptors,”
  44. M.H.Trivedi,A.J.Rush,S.R.Wisniewskietal.,“Evaluationof outcomes with citalopram for depression using measurementbased care in STAR∗D: implications for clinical practice,” AmericanJournalofPsychiatry,vol.163,no.1,pp.28–40,2006.
  45. (2009). Mecamylamine a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders,”
  46. (2002). Mechanisms of nicotine actions on dorsal raphe serotoninergic neurons,”
  47. (2006). Musachio et al., “Sazetidine-a, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors
  48. (2007). Neuro-immune interactions via the cholinergic anti-inflammatory pathway,”
  49. (2002). Neuronal nicotinic receptor inhibition for treatingmooddisorders:preliminarycontrolledevidencewith mecamylamine,”DepressionandAnxiety,vol.16,no.3,pp.89– 92,
  50. (2005). Nicotine addiction and comorbiditywith alcohol abuse andmental illness,”
  51. (2003). Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram,”
  52. (2009). Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests,”
  53. (2002). Nicotinic acetylcholine receptors6 The Scientific World Journal as targets for antidepressants,”
  54. (2010). Nicotinic partial agonists varenicline and sazetidine-a have differential effects on affective behavior,”
  55. (2010). Nicotinic receptor mechanisms in neuropsychiatric disorders: therapeutic implications,”
  56. (2001). oikar ,S.K oks,E.V asar ,andH.Rauvala,“Strainandgender differences in the behavior of mouse lines commonly used in transgenic studies,”
  57. (2009). P h i l i p ,L .L .C a rp e n t e r ,A .R .T yrk a ,L .B .W h i t e l ey ,a n dL
  58. (2012). Partial agonists for alpha4beta2 nicotinic receptors stimulate dopamine neuron firing with relatively enhanced maximal effects,”
  59. (2010). Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence,”
  60. (1912). Presynaptic nicotinic receptors facilitate monoaminergic transmission,”JournalofNeuroscience,vol.18,no.5,pp.1904–
  61. (2010). Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis,”
  62. (2011). R.West,W.Zatonski,M.Cedzynskaetal.,“Placebo-controlled trial of cytisine for smoking cessation,” The New England
  63. (2002). Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure,”
  64. (2009). side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline,”
  65. (2002). sleep changes with acute nicotine administration in nonsmoking major depressed patients,”
  66. (2008). Spirling et al., “Varenicline in the routine treatment of tobacco dependence: a prepost comparison with nicotine replacement therapy and an evaluation in those with mental illness,”
  67. (2011). Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test,”
  68. (2011). Suicidal behavior and depression in smoking cessation treatments,”
  69. (2008). Tc-5214 (S(+)-mecamylamine): a neuronal nicotinic receptor modulator withantidepressantactivity,”CNSNeuroscienceandTherapeutics,
  70. (1986). The antinociceptive action of some β-adrenoceptor agonists in mice,”
  71. (2006). The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice,”
  72. (1993). The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals withnicotinicacetylcholinereceptor-likeimmunoreactivityin themedian eminence
  73. (2007). The role of dopamine in the pathophysiology of depression,”
  74. (1985). The tail suspensiontest:anewmethodforscreeningantidepressantsin mice,”
  75. (2006). Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial,”
  76. (2009). Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database,”
  77. (2009). Varenicline improves mood and cognition during smoking abstinence,”
  78. (2007). Varenicline-induced manic episode in a patient with bipolar disorder [8],”
  79. (2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial,”
  80. (2005). Varenicline: an alpha;4β2 nicotinic receptor partial agonist for smoking cessation,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.